JP2024537139A5 - - Google Patents

Info

Publication number
JP2024537139A5
JP2024537139A5 JP2024520707A JP2024520707A JP2024537139A5 JP 2024537139 A5 JP2024537139 A5 JP 2024537139A5 JP 2024520707 A JP2024520707 A JP 2024520707A JP 2024520707 A JP2024520707 A JP 2024520707A JP 2024537139 A5 JP2024537139 A5 JP 2024537139A5
Authority
JP
Japan
Prior art keywords
inhibitor
kras
salt
pharmaceutically acceptable
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520707A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/045619 external-priority patent/WO2023059594A1/en
Publication of JP2024537139A publication Critical patent/JP2024537139A/ja
Publication of JP2024537139A5 publication Critical patent/JP2024537139A5/ja
Pending legal-status Critical Current

Links

JP2024520707A 2021-10-05 2022-10-04 KRAS G12D阻害剤とPI3Ka阻害剤との組み合わせ及び関連する治療方法 Pending JP2024537139A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252384P 2021-10-05 2021-10-05
US63/252,384 2021-10-05
PCT/US2022/045619 WO2023059594A1 (en) 2021-10-05 2022-10-04 Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment

Publications (2)

Publication Number Publication Date
JP2024537139A JP2024537139A (ja) 2024-10-10
JP2024537139A5 true JP2024537139A5 (cg-RX-API-DMAC7.html) 2025-09-30

Family

ID=85803703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520707A Pending JP2024537139A (ja) 2021-10-05 2022-10-04 KRAS G12D阻害剤とPI3Ka阻害剤との組み合わせ及び関連する治療方法

Country Status (10)

Country Link
US (1) US20240408098A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412716A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537139A (cg-RX-API-DMAC7.html)
KR (1) KR20240073112A (cg-RX-API-DMAC7.html)
CN (1) CN118338904A (cg-RX-API-DMAC7.html)
AU (1) AU2022359282A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233566A1 (cg-RX-API-DMAC7.html)
IL (1) IL311834A (cg-RX-API-DMAC7.html)
MX (1) MX2024004213A (cg-RX-API-DMAC7.html)
WO (1) WO2023059594A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
US20250120981A1 (en) * 2023-10-12 2025-04-17 Mirati Therapeutics, Inc. Mrtx1133 pharmaceutical compositions
CN122459678A (zh) 2023-12-29 2026-07-24 百时美施贵宝公司 KRAS抑制剂与Treg耗竭剂的组合疗法
WO2026080796A1 (en) * 2024-10-11 2026-04-16 Mirati Therapeutics, Inc. Mrtx1133 capsule pharmaceutical compositions
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
ES2738864T3 (es) 2013-03-12 2020-01-27 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combinaciones de inhibidores de MEK, EGFR y ERBB2 en el tratamiento del cáncer de pulmón causado por un mutante de KRAS
AU2019355574A1 (en) 2018-10-05 2021-05-06 Sloan-Kettering Institute For Cancer Research PI3K inhibitors and uses thereof
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021106231A1 (en) * 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
WO2022076917A1 (en) * 2020-10-08 2022-04-14 Kumquat Biosciences Inc. Modulators of cell proliferation and uses thereof

Similar Documents

Publication Publication Date Title
JP2024537140A5 (cg-RX-API-DMAC7.html)
JP2024537136A5 (cg-RX-API-DMAC7.html)
JP2022548791A5 (cg-RX-API-DMAC7.html)
JP2025000632A5 (cg-RX-API-DMAC7.html)
JP2024537137A5 (cg-RX-API-DMAC7.html)
JP2025000629A5 (cg-RX-API-DMAC7.html)
JP2025000630A5 (cg-RX-API-DMAC7.html)
FI3849537T3 (fi) Yhdistelmäterapioita
JP2024540839A5 (cg-RX-API-DMAC7.html)
JP2024521788A5 (cg-RX-API-DMAC7.html)
CN105311030B (zh) 用于抗肿瘤的螺取代化合物
JP6141958B2 (ja) 増殖性疾患の治療のための併用療法(ベムラフェニブ及びmdm2阻害剤)
IL311834A (en) Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods
JP2002532392A5 (cg-RX-API-DMAC7.html)
JP2025512999A5 (cg-RX-API-DMAC7.html)
Kojonazarov et al. Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling
IL311863A (en) Combinations of KRAS G12D inhibitors and irinotecan and therapeutic methods
CN107296811B (zh) 一种用于治疗胃癌的喹啉衍生物
CN111035639A (zh) 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物
JP2016507500A5 (cg-RX-API-DMAC7.html)
IL315645A (en) Combination therapies comprising a sos1 inhibitor and an egfr inhibitor
WO2007113243A2 (en) Use of pde 5 inhibitors for the treatment of overactive bladder
WO2007123511A2 (en) Dosing regimens for the treatment of cancer
JP6370801B2 (ja) 肝疾患または肝障害の治療のための使用および方法
JP2025513802A5 (cg-RX-API-DMAC7.html)